בריפלקס PN 250

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN

Pieejams no:

CSL BEHRING LTD., ISRAEL

ATĶ kods:

B02BD01

Zāļu forma:

אבקה וממס להכנת תמיסה להזרקה

Kompozīcija:

COAGULATION FACTOR II (HUMAN) 200 - 480 IU; COAGULATION FACTOR VII (HUMAN) 100 - 250 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 200 - 310 IU; COAGULATION FACTOR X (HUMAN) 220 - 600 IU; PROTEIN C 150 - 450 IU; PROTEIN S ANTIGEN 120 - 380 IU

Ievadīšanas:

תוך-ורידי

Receptes veids:

מרשם נדרש

Ražojis:

CSL BEHRING GmbH, GERMANY

Ārstniecības grupa:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Ārstniecības joma:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Ārstēšanas norādes:

-Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.

Autorizācija datums:

2017-03-31